BioXcel Therapeutics IncNASDAQ:BTAI
- LAST PRICE1.1500
- TODAY'S CHANGE (%)-0.0200 (-1.7094%)
- Bid / Lots1.1500/ 20
- Ask / Lots1.1700/ 1
- Open / Previous Close1.2000 / 1.1700
- Day Range
- 52 Week Range
- Volume259,643
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BTAI |
|---|---|---|
| 09:32 ET | 2398 | 1.2 |
| 09:36 ET | 2000 | 1.181 |
| 09:45 ET | 900 | 1.19 |
| 09:48 ET | 300 | 1.19 |
| 09:50 ET | 531 | 1.1983 |
| 09:52 ET | 731 | 1.19 |
| 09:54 ET | 710 | 1.1901 |
| 09:56 ET | 200 | 1.195 |
| 09:57 ET | 200 | 1.195 |
| 10:01 ET | 424 | 1.1918 |
| 10:03 ET | 7991 | 1.19 |
| 10:10 ET | 355 | 1.1901 |
| 10:12 ET | 6098 | 1.18 |
| 10:17 ET | 1575 | 1.18 |
| 10:19 ET | 100 | 1.18 |
| 10:24 ET | 1802 | 1.1701 |
| 10:32 ET | 17418 | 1.15 |
| 10:33 ET | 2368 | 1.15 |
| 10:35 ET | 796 | 1.14 |
| 10:37 ET | 250 | 1.14 |
| 10:42 ET | 6288 | 1.16 |
| 10:44 ET | 500 | 1.16 |
| 10:46 ET | 100 | 1.16 |
| 10:55 ET | 600 | 1.155 |
| 10:57 ET | 7205 | 1.16 |
| 11:00 ET | 494 | 1.16 |
| 11:02 ET | 149 | 1.155 |
| 11:08 ET | 300 | 1.155 |
| 11:09 ET | 10031 | 1.155 |
| 11:11 ET | 11363 | 1.135 |
| 11:13 ET | 1500 | 1.13 |
| 11:15 ET | 49686 | 1.155 |
| 11:18 ET | 100 | 1.16 |
| 11:20 ET | 100 | 1.16 |
| 11:22 ET | 1619 | 1.18 |
| 11:24 ET | 400 | 1.17 |
| 11:26 ET | 300 | 1.16 |
| 11:31 ET | 1100 | 1.1799 |
| 11:33 ET | 220 | 1.175 |
| 11:38 ET | 450 | 1.175 |
| 11:45 ET | 100 | 1.175 |
| 11:47 ET | 100 | 1.175 |
| 11:51 ET | 211 | 1.1796 |
| 11:56 ET | 428 | 1.175 |
| 12:03 ET | 204 | 1.17 |
| 12:09 ET | 5470 | 1.18 |
| 12:12 ET | 1119 | 1.18 |
| 12:14 ET | 5710 | 1.185 |
| 12:20 ET | 556 | 1.1801 |
| 12:38 ET | 2800 | 1.18 |
| 12:39 ET | 3489 | 1.18 |
| 12:45 ET | 1144 | 1.175 |
| 12:48 ET | 100 | 1.175 |
| 01:06 ET | 5217 | 1.17 |
| 01:12 ET | 200 | 1.17 |
| 01:15 ET | 287 | 1.1735 |
| 01:17 ET | 400 | 1.175 |
| 01:33 ET | 230 | 1.18 |
| 01:35 ET | 460 | 1.175 |
| 01:42 ET | 182 | 1.18 |
| 01:44 ET | 320 | 1.1775 |
| 02:26 ET | 700 | 1.18 |
| 02:27 ET | 100 | 1.175 |
| 02:36 ET | 255 | 1.17 |
| 02:40 ET | 100 | 1.175 |
| 03:00 ET | 15773 | 1.16 |
| 03:02 ET | 500 | 1.1681 |
| 03:03 ET | 2700 | 1.165 |
| 03:05 ET | 700 | 1.16 |
| 03:07 ET | 394 | 1.165 |
| 03:09 ET | 200 | 1.165 |
| 03:16 ET | 846 | 1.1665 |
| 03:18 ET | 7871 | 1.16 |
| 03:20 ET | 700 | 1.155 |
| 03:21 ET | 2898 | 1.1585 |
| 03:32 ET | 100 | 1.155 |
| 03:36 ET | 6034 | 1.17 |
| 03:43 ET | 1391 | 1.165 |
| 03:45 ET | 1471 | 1.16 |
| 03:48 ET | 300 | 1.16 |
| 03:50 ET | 500 | 1.1615 |
| 03:52 ET | 2226 | 1.165 |
| 03:54 ET | 100 | 1.16 |
| 03:56 ET | 1500 | 1.16 |
| 03:57 ET | 3241 | 1.16 |
| 03:59 ET | 13734 | 1.15 |
Jul 16, 2024
DJ BioXcel Therapeutics Shares Rise 7% After 2Q Igalmi Guidance, from 12:19PM ET on Tuesday Jul 16, 2024 by Dow Jones
12:19PM ET on Tuesday Jul 16, 2024 by Dow JonesBioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI(TM) (dexmedetomidine) Sublingual Film, from 7:00AM ET on Tuesday Jul 16, 2024 by Dow Jones
7:00AM ET on Tuesday Jul 16, 2024 by Dow Jones
Jun 27, 2024
DJ BioXcel Therapeutics Is Maintained at Buy by Canaccord Genuity, from 9:42AM ET on Thursday Jun 27, 2024 by Dow Jones
9:42AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioXcel Therapeutics Inc | 43.9M | -0.2x | --- |
OncoCyte Corp | 44.9M | -0.7x | --- |
Matinas BioPharma Holdings Inc | 42.5M | -1.6x | --- |
Longeveron Inc | 43.7M | -0.4x | --- |
Provectus Biopharmaceuticals Inc | 48.0M | -15.9x | --- |
NextCure Inc | 44.2M | -0.7x | --- |
Company Information
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Contact Information
- Headquarters
- 555 Long Wharf DrNEW HAVEN, CT, United States 06511-6107
- Phone
- 203-643-8060
- Fax
- 302-636-5454
Executives
- Lead Independent Chairman of the Board
- Peter Mueller
- President, Chief Executive Officer, Director
- Vimal Mehta
- Chief Financial Officer, Senior Vice President
- Richard Steinhart
- Executive Vice President, Chief Scientific Officer
- Frank Yocca
- Executive Vice President, Chief of Product Development and Medical Officer
- Vincent O'Neill
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.9M |
|---|---|
Revenue (TTM) | $1.8M |
Shares Outstanding | 37.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $-5.18 |
Book Value | $-1.89 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 25.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,243.11% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
